ArticleAsian Pacific journal of cancer prevention : APJCP2025
Anti-Angiogenic and Anti-Proliferative Activities of 5-Bromo-N-(2,5-Dioxopyrrolidin-1-Yl)-1H-Indole-2-Carboxamide.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis has long been a key focus for drug designers aiming to develop therapies targeting diseases associated with this physiological process. A newly synthesized compound from the University of Baghdad was evaluated for its ability to inhibit blood vessel growth. The objective of this study was to investigate the anti-angiogenic activity of 5-bromo-N-(2,5-dioxopyrrolidin-1-yl)-1H-indole-2-carboxamide using an ex vivo rat aorta model.
methodsAn anti-angiogenesis assay was employed to assess the dose-response relationship and to determine the concentration that inhibits 50% of blood vessel growth (IC50). The anti-proliferative effect on endothelial cells was assessed using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. Additionally, the free radical scavenging activity of the compound was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. The anti-proliferative activity against the A549 lung cancer cell line was also investigated.
resultsThe compound demonstrated significant anti-angiogenic activity with an IC50 of 15.4 µg/mL. The IC50 on the HUVEC cell line was 5.6 µg/mL. Its free radical scavenging activity was measured at 99.6 µg/mL. Furthermore, the compound significantly inhibited the proliferation of the A549 lung cancer cell line, with an IC50 of 14.4 µg/mL.
conclusionThe findings suggest that 5-bromo-N-(2,5-dioxopyrrolidin-1-yl)-1H-indole-2-carboxamide possesses notable anti-angiogenic activity and a significant anti-proliferative effect on HUVEC cells, potentially linked to its strong free radical scavenging capacity. Moreover, it effectively inhibited the proliferation of lung cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.